aap Implantate AG
- WKN: A3H210
- ISIN: DE000A3H2101
- Land: Deutschland
Nachricht vom 20.10.2021 | 18:31
Result of the capital increase with subscription rights: capital measure significantly oversubscribed; issue of 1.5 million new shares leads to gross issue proceeds of almost EUR 5 million
aap Implantate AG / Key word(s): Capital Increase/Financing
The Management Board of aap Implantate AG ("aap" or the "Company") announces that, following completion of the private placement as part of the capital increase with subscription rights, demand for new shares in aap was significantly higher than the total volume of the capital measure with 1.5 million offered new shares. The capital increase is therefore oversubscribed.
On 20 October 2021 the Company's Management Board therefore resolved, with the approval of the Supervisory Board of the same day, to implement the capital increase against cash contributions out of the authorized capital 2019/I with subscription and oversubscription rights of the Company's shareholders resolved by the Management Board and Supervisory Board on 27 September 2021 in full. As part of the capital increase, 1,500,000 new no-par value bearer shares in aap with a pro rata amount of the share capital of EUR 1.00 each and with dividend rights from 1 January 2021 ("New Shares") will thus be issued. All of the shares offered as part of the subscription offer were thus subscribed by shareholders or placed with investors by way of private placement.
The capital increase with subscription rights raises aap's share capital by EUR 1,500,000.00 from the current EUR 3,478,243.00 to EUR 4,978,243.00. The New Shares were issued at a subscription price of EUR 3.30. Consequently, the capital measure results in gross issue proceeds of EUR 4.95 million, of which the Company will receive net inflows of approximately EUR 4.8 million in the short term after deduction of consulting fees and other costs.
The issue proceeds from the transaction shall be used to finance the planned sales growth with a focus on the USA (especially investments in sets) and the start of the human clinical study for aap's antibacterial silver coating technology in the fourth quarter of 2021.
For queries, please contact:
aap Implantate AG; Fabian Franke; Head of Investor Relations; Lorenzweg 5; 12099 Berlin, Germany; Phone: +49 (0)30 75019 - 134; Fax: +49 (0)30 75019 - 290; Email: email@example.com
|Company:||aap Implantate AG|
|Phone:||+49 (0) 30 75 01 90|
|Fax:||+49 (0) 30 75 01 91 11|
|Listed:||Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange|
|EQS News ID:||1242303|
|End of Announcement||DGAP News Service|
GBC im Fokus
IGEA Pharma N.V. Realignment to CBD extraction
The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.
Der AKTIONÄR News
29. November 06:35 DAX nach Kursrutsch im Plus erwartet, Omikron-Variante im Fokus, ...
29. November 06:39 Commerzbank: Rebound nach Absturz?
29. November 06:49 Varta-Aktie: 76 oder 140 Euro – welcher Experte behält recht?
29. November 06:50 Vulcan Energy: "Wichtiges Signal für den europäischen Lithium-Markt"
29. November 07:00 Gerd Weger: "Der Kryptomarkt verspricht weiter Renditen von 100 ...
Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten
26. November 2021